Genmab reports high objective response rates for petosemtamab in Phase 2 colorectal cancer trial
+2 new sources since this summary was written
Genmab A/S announced updated Phase 2 data for petosemtamab combined with chemotherapy in metastatic colorectal cancer. The trial of 79 patients showed a 75% objective response rate (ORR) in first‑line and 67% in second‑line patients, with an 81% ORR in first‑line left‑sided tumors. Disease control rates were 95% and 93% respectively, and the results were presented at the ESMO 2026 Congress.
Why it matters
The company says the data support its ongoing four Phase 3 programs and signal a shift into late‑stage gastrointestinal oncology, which could improve future revenue potential. Investors may view the strong response rates as a catalyst for the upcoming Phase 3 trials.
Key facts
- 1The Phase 2 trial evaluated 79 patients (45 first‑line, 34 second‑line) as of May 15 2026. investing.com
- 2Confirmed and unconfirmed ORR was 75% in first‑line patients at a median follow‑up of 5.9 months. investing.com
- 3Confirmed and unconfirmed ORR was 67% in second‑line patients at a median follow‑up of 7.1 months. investing.com
- 4ORR among first‑line patients with left‑sided tumors was 81%. investing.com
- 5Disease control rates were 95% in first‑line and 93% in second‑line patients. investing.com
- 6Treatment‑emergent adverse events led to discontinuation in 2 of 42 patients on petosemtamab + mFOLFOX6 and 1 of 37 on petosemtamab + FOLFIRI. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.